9:05 am Karyopharm Therapeutics announces initiation of an investigator sponsored Phase 1 dose escalation study of its lead drug candidate Selinexor (KPT-330) in Singapore
View todays social media effects on KPTI
View the latest stocks trending across Twitter. Click to view dashboard
See who Karyopharm is hiring next, click here to view
